Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Altamira’s Bentrio nasal spray approved in Malaysia

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio nasal spray has been approved by the Medical Device Authority of Malaysia for the protection against airborne allergens and viruses and is cleared for commercialization in...

January 21, 2022

Developments

Dyadic introduces novel method to produce synthetic cannabinoids

Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...

January 21, 2022

Developments

FSD launches new corporate website to convey its emerging position in pharma

FSD Pharma (NASDAQ, CSE:HUGE; FRA:0K9A) launched a newly designed website to convey its emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and...

January 20, 2022

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Markets

BTIG cuts Acutus Medical to neutral from buy

BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...

January 20, 2022

Markets

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

SVB Leerink upgraded Calithera Biosciences (NASDAQ:CALA) to “outperform” from “market perform” and raised its price target to $3 from $1. The stock closed at 49 cents on Jan. 19. “We conducted a deeper dive on...

January 20, 2022

Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022

Markets

Maxim starts INVO Bioscience at buy; PT $7

Maxim Group launched coverage of INVO Biosciences (NASDAQ:INVO) with a “buy” rating and $7 price target. The stock closed at $3.69 on Jan. 18. INVO is a commercial-stage company with the world’s first and only...

January 19, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Markets

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

January 18, 2022

Developments

FSD Pharma’s Dr. Eleanor Fish named to Order of Canada

Eleanor Fish, Ph.D., a member of FSD Pharma’s (NASDAQ, CSE:HUGE; FRA: 0K9A) research and clinical advisory board, was appointed to the Order of Canada for her contributions to immunology, including her ground-breaking...

January 18, 2022

Developments

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...

January 18, 2022

Altamira’s Bentrio nasal spray approved in Malaysia

Dyadic introduces novel method to produce synthetic cannabinoids

FSD launches new corporate website to convey its emerging position in pharma

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

BTIG cuts Acutus Medical to neutral from buy

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim starts INVO Bioscience at buy; PT $7

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

Maxim ups Daré Biosciences PT to $4 from $3

FSD Pharma’s Dr. Eleanor Fish named to Order of Canada

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

General

More

Sign up for the BioTuesdays weekly newsletter